JP7565118B2 - (s,e)-4-(ジメチルアミノ)-n-(3-(4-(2-ヒドロキシ-1-フェネチルアミノ)-6-フェニルフロ[2,3-d]ピリミジン-5-イル)フェニル)ブタ-2-エナミド遊離塩基の結晶形 - Google Patents

(s,e)-4-(ジメチルアミノ)-n-(3-(4-(2-ヒドロキシ-1-フェネチルアミノ)-6-フェニルフロ[2,3-d]ピリミジン-5-イル)フェニル)ブタ-2-エナミド遊離塩基の結晶形 Download PDF

Info

Publication number
JP7565118B2
JP7565118B2 JP2023544357A JP2023544357A JP7565118B2 JP 7565118 B2 JP7565118 B2 JP 7565118B2 JP 2023544357 A JP2023544357 A JP 2023544357A JP 2023544357 A JP2023544357 A JP 2023544357A JP 7565118 B2 JP7565118 B2 JP 7565118B2
Authority
JP
Japan
Prior art keywords
cancer
crystalline form
pharmaceutical composition
abt
free base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023544357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514995A (ja
JP2024514995A5 (cg-RX-API-DMAC7.html
Inventor
ツー-アン スー,
シン-パン シェ,
スー-ミン チャン,
Original Assignee
アンボーゲン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンボーゲン セラピューティクス インコーポレイテッド filed Critical アンボーゲン セラピューティクス インコーポレイテッド
Publication of JP2024514995A publication Critical patent/JP2024514995A/ja
Publication of JP2024514995A5 publication Critical patent/JP2024514995A5/ja
Application granted granted Critical
Publication of JP7565118B2 publication Critical patent/JP7565118B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2023544357A 2021-07-06 2022-07-06 (s,e)-4-(ジメチルアミノ)-n-(3-(4-(2-ヒドロキシ-1-フェネチルアミノ)-6-フェニルフロ[2,3-d]ピリミジン-5-イル)フェニル)ブタ-2-エナミド遊離塩基の結晶形 Active JP7565118B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163218504P 2021-07-06 2021-07-06
US63/218,504 2021-07-06
PCT/US2022/036260 WO2023283269A1 (en) 2021-07-06 2022-07-06 Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base

Publications (3)

Publication Number Publication Date
JP2024514995A JP2024514995A (ja) 2024-04-04
JP2024514995A5 JP2024514995A5 (cg-RX-API-DMAC7.html) 2024-08-20
JP7565118B2 true JP7565118B2 (ja) 2024-10-10

Family

ID=84802010

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544357A Active JP7565118B2 (ja) 2021-07-06 2022-07-06 (s,e)-4-(ジメチルアミノ)-n-(3-(4-(2-ヒドロキシ-1-フェネチルアミノ)-6-フェニルフロ[2,3-d]ピリミジン-5-イル)フェニル)ブタ-2-エナミド遊離塩基の結晶形

Country Status (12)

Country Link
US (2) US12240858B2 (cg-RX-API-DMAC7.html)
EP (1) EP4330259A4 (cg-RX-API-DMAC7.html)
JP (1) JP7565118B2 (cg-RX-API-DMAC7.html)
KR (1) KR102783648B1 (cg-RX-API-DMAC7.html)
CN (1) CN116916922B (cg-RX-API-DMAC7.html)
AU (1) AU2022307875B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023024853A2 (cg-RX-API-DMAC7.html)
CA (1) CA3217088A1 (cg-RX-API-DMAC7.html)
IL (1) IL308946B2 (cg-RX-API-DMAC7.html)
MX (1) MX2023013093A (cg-RX-API-DMAC7.html)
TW (1) TWI809967B (cg-RX-API-DMAC7.html)
WO (1) WO2023283269A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI906763B (zh) * 2024-02-05 2025-12-01 財團法人國家衛生研究院 表皮生長因子受體抑制劑

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100120805A1 (en) 2008-11-10 2010-05-13 National Health Research Institutes Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors
WO2011099764A2 (en) 2010-02-09 2011-08-18 Hanmi Holdings Co., Ltd. Novel pyrimidine derivative for inhibiting the growth of cancer cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100120805A1 (en) 2008-11-10 2010-05-13 National Health Research Institutes Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors
WO2011099764A2 (en) 2010-02-09 2011-08-18 Hanmi Holdings Co., Ltd. Novel pyrimidine derivative for inhibiting the growth of cancer cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry,2019年,Vol. 62,pp. 10108-10123

Also Published As

Publication number Publication date
MX2023013093A (es) 2024-04-09
TW202309041A (zh) 2023-03-01
IL308946A (en) 2024-01-01
AU2022307875A1 (en) 2023-11-02
CN116916922A (zh) 2023-10-20
IL308946B2 (en) 2026-01-01
JP2024514995A (ja) 2024-04-04
IL308946B1 (en) 2025-09-01
CA3217088A1 (en) 2023-01-12
KR102783648B1 (ko) 2025-03-18
US20230021909A1 (en) 2023-01-26
US20240368175A1 (en) 2024-11-07
WO2023283269A1 (en) 2023-01-12
CN116916922B (zh) 2026-01-02
US12240858B2 (en) 2025-03-04
BR112023024853A2 (pt) 2024-02-15
AU2022307875B2 (en) 2024-08-01
KR20230118963A (ko) 2023-08-14
TWI809967B (zh) 2023-07-21
EP4330259A4 (en) 2024-10-09
EP4330259A1 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
JP7383652B2 (ja) B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
JP4456079B2 (ja) {6,7−ビス(2−メトキシ−エトキシ)−キナゾリン−4−イル}−(3e)の多形体
TW202311259A (zh) 化合物i的新形式及其應用
CN109153669B (zh) 苯甲酰胺类化合物的新晶型
AU2019218186B2 (en) Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof
AU2018283289B2 (en) Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
CN109476634B (zh) 喹唑啉衍生物的盐的晶体
CN107793363B (zh) 一种取代芳胺基芳杂环类化合物及其作为抗肿瘤药物的应用
KR102783648B1 (ko) (s, e)-4-(디메틸아미노)-n-(3-(4-(2-히드록시-1-페닐에틸아미노)-6-페닐퓨로[2,3-d]피리미딘-5-일)페닐)부트-2-엔아미드 유리 염기의 결정형
RU2851691C2 (ru) Кристаллические формы свободного основания (S,E)-4-(диметиламино)-N-(3-(4-(2-гидрокси-1-фенилэтиламино)-6-фенилфуро[2,3-d]пиримидин-5-ил)фенил)бут-2-енамида
CN120344512A (zh) 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
HK40094095A (en) Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base
EP3750894B1 (en) Urea-substituted aromatic ring-linked dioxazoline compound, preparation method therefor, and uses thereof
TW201125861A (en) CDC7 inhibitor salts
TWI596098B (zh) 埃克替尼馬來酸鹽的晶型及其用途
TW202517624A (zh) Mek免疫腫瘤抑制劑醫藥組合物
CN119095838A (zh) 5-(2-(4-(4-氟-2-甲基-1h-吲哚-5-基氧基)-6-甲氧基喹啉-7-基氧基)乙基)-5-氮杂螺[2.4]-庚-7-醇(化合物a)结晶、磷酸盐以及其对映异构体的生物活性
KR20210050530A (ko) 신규 아자트리시클릭 화합물의 염 형태 및 결정 형태 및 그의 용도
TW201506029A (zh) 埃克替尼的晶型及其應用
OA19085A (en) Pharmaceutical salts of N-(2-(2(dimethylamino)ethoxy)-4-methoxy-5-((4-(1methyl-1H-indol-3-yl)pyrimidin-2-yl)amino) phenyl)acrylamide and crystalline forms thereof
HK1261832B (en) Crystal of salt of quinazoline derivative

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231017

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240809

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240920

R150 Certificate of patent or registration of utility model

Ref document number: 7565118

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150